Royalty Pharma plc Financing Cash Flow
Royalty Pharma plc (RPRX) reported Financing Cash Flow of -$545.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Royalty Pharma plc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$273.15M.
- Royalty Pharma plc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$272.67M.
- Royalty Pharma plc net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$299.60M.
- Royalty Pharma plc net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $562.74M.
- Royalty Pharma plc net cash provided by (used in) financing activities for fiscal 2025 was -$1.19B, a 428.39% decline from fiscal 2024.
- Royalty Pharma plc net cash provided by (used in) financing activities for fiscal 2024 was $361.14M.
- Royalty Pharma plc net cash provided by (used in) financing activities for fiscal 2023 was -$2.15B.
- Royalty Pharma plc net cash provided by (used in) financing activities for fiscal 2022 was -$944.86M, a 345.35% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$273.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$545.82M 10-Q · filed 2026-08-05 | -$845.41M derived: sum of 3 quarters · filed 2026-08-05 | -$282.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$272.67M 10-Q · filed 2026-05-06 | -$572.26M derived: sum of 2 quarters · filed 2026-05-06 | -$9.53M derived: sum of 3 quarters · filed 2026-05-06 | -$517.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$299.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $263.14M derived: sum of 2 quarters · filed 2026-02-11 | -$244.67M derived: sum of 3 quarters · filed 2026-08-05 | -$1.19B 10-K · filed 2026-02-11 |
| 2025-09-30 | $562.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $54.92M derived: sum of 2 quarters · filed 2026-08-05 | -$886.38M 10-Q · filed 2025-11-05 | -$1.14B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$507.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.45B 10-Q · filed 2026-08-05 | -$1.71B derived: sum of 3 quarters · filed 2026-08-05 | -$2.03B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$941.30M 10-Q · filed 2026-05-06 | -$1.20B derived: sum of 2 quarters · filed 2026-05-06 | -$1.52B derived: sum of 3 quarters · filed 2026-05-06 | -$368.16M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$257.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$583.47M derived: sum of 2 quarters · filed 2026-02-11 | $573.14M derived: sum of 3 quarters · filed 2026-02-11 | $361.14M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$325.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $831.11M derived: sum of 2 quarters · filed 2025-11-05 | $619.11M 10-Q · filed 2025-11-05 | $387.21M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $1.16B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $944.61M 10-Q · filed 2025-08-06 | $712.72M derived: sum of 3 quarters · filed 2026-02-11 | -$646.77M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$212.00M 10-Q · filed 2025-05-08 | -$443.89M derived: sum of 2 quarters · filed 2026-02-11 | -$1.80B derived: sum of 3 quarters · filed 2026-02-11 | -$2.15B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | -$231.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$1.59B derived: sum of 2 quarters · filed 2026-02-11 | -$1.94B derived: sum of 3 quarters · filed 2026-02-11 | -$2.15B 10-K · filed 2026-02-11 |
| 2023-09-30 | -$1.36B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.71B derived: sum of 2 quarters · filed 2024-11-06 | -$1.92B 10-Q · filed 2024-11-06 | -$2.18B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -$347.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$557.37M 10-Q · filed 2024-08-08 | -$822.92M derived: sum of 3 quarters · filed 2025-02-12 | -$1.05B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$210.37M 10-Q · filed 2024-05-09 | -$475.92M derived: sum of 2 quarters · filed 2025-02-12 | -$706.01M derived: sum of 3 quarters · filed 2025-02-12 | -$934.26M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$265.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$495.64M derived: sum of 2 quarters · filed 2025-02-12 | -$723.89M derived: sum of 3 quarters · filed 2025-02-12 | -$944.86M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$230.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$458.34M derived: sum of 2 quarters · filed 2023-11-08 | -$679.31M 10-Q · filed 2023-11-08 | -$877.38M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$228.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$449.22M 10-Q · filed 2023-08-08 | -$647.29M derived: sum of 3 quarters · filed 2024-02-15 | $386.98M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$220.97M 10-Q · filed 2023-05-09 | -$419.04M derived: sum of 2 quarters · filed 2024-02-15 | $615.23M derived: sum of 3 quarters · filed 2024-02-15 | $390.82M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$198.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $836.20M derived: sum of 2 quarters · filed 2024-02-15 | $611.78M derived: sum of 3 quarters · filed 2024-02-15 | $385.11M 10-K · filed 2024-02-15 |
| 2021-09-30 | $1.03B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $809.85M derived: sum of 2 quarters · filed 2022-11-08 | $583.18M 10-Q · filed 2022-11-08 | $305.79M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | -$224.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$451.08M 10-Q · filed 2022-08-04 | -$728.48M derived: sum of 3 quarters · filed 2023-02-15 | -$1.09B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$226.67M 10-Q · filed 2022-05-05 | -$504.06M derived: sum of 2 quarters · filed 2023-02-15 | -$861.45M derived: sum of 3 quarters · filed 2023-02-15 | $717.98M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | -$277.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$634.78M derived: sum of 2 quarters · filed 2023-02-15 | $944.65M derived: sum of 3 quarters · filed 2023-02-15 | $1.49B 10-K · filed 2023-02-15 |
| 2020-09-30 | -$357.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.22B derived: sum of 2 quarters · filed 2021-11-10 | $1.76B 10-Q · filed 2021-11-10 | $1.48B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $1.58B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $2.12B 10-Q · filed 2021-08-11 | $1.84B derived: sum of 3 quarters · filed 2022-02-15 | $1.56B derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $542.52M 10-Q · filed 2021-05-11 | $256.72M derived: sum of 2 quarters · filed 2022-02-15 | -$23.97M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | -$285.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$566.49M derived: sum of 2 quarters · filed 2022-02-15 | -$1.19B 10-K · filed 2022-02-15 | |
| 2019-09-30 | -$280.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$905.82M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$625.13M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | -$1.38B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |